Pacific Biosciences sees Q4 revenue $27.3M, consensus $27.88M

Received orders for 96 instruments in the fourth quarter, which included orders for 76 Revio systems for delivery in 2023. Expect preliminary unaudited fourth quarter revenue of approximately $27.3 million, representing a decrease of approximately 24% compared with $36.0 million for the fourth quarter of 2021. As a result, preliminary unaudited annual 2022 revenue is expected to be approximately $128.2 million, representing a decline of 2% from 2021. FY22 consensus $128.97M.